[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:idiopathic-inflammatory-myopathy":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":130,"states":131},"Idiopathic Inflammatory Myopathy",19,15,[8,16,23,29,35,41,47,53,60,66,73,80,86,92,98,104,111,117,123],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07160205","Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis\u002F Polymyositis (DM\u002FPM), Also Known as Idiopathic Inflammatory Myopathy (IIM)",[12],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.362461Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07085104","A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",[20],"Phase 1","2026-08-26T02:16:26.411851Z","2026-07-30T01:46:14.415751Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05869955","A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)",[20],"2026-08-03T03:31:16.569358Z","2026-05-05T02:43:29.019382Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07295847","A Study of AZD0120 in Autoimmune Diseases",[20],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.813958Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06916806","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.",[20],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.362747Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07115745","A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases",[20],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.679553Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06925542","A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease",[20],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:27.245332Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT06991114","AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.",[57],"Phase 2","2026-08-26T02:19:00.742020Z","2026-05-05T02:43:26.665133Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06308978","A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",[20],"2026-08-26T02:15:13.282904Z","2026-04-29T02:57:57.084867Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT06733935","A Phase 1\u002F2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)",[70],"Phase 1\u002FPhase 2","2026-08-26T02:18:18.766496Z","2026-06-16T05:54:07.925914Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":78,"content_modified":79},"NCT06572384","A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease",[77],"Phase 3","2026-08-26T02:18:02.701182Z","2026-05-05T02:43:28.672548Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT06154252","RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy",[12],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:27.760583Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT07220915","Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections",[77],"2026-08-26T02:17:05.997056Z","2026-07-24T01:27:14.901588Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT01422694","Natural History and Development of Spondyloarthritis",[],"2026-08-26T02:18:15.214990Z","2026-07-19T19:36:05.096286Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07374107","MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)",[],"2026-08-26T02:16:41.943926Z","2026-05-13T02:55:06.697864Z",{"nct_id":105,"title":106,"phases":107,"status":108,"updated_at":109,"content_modified":110},"NCT07038447","A Study of KITE-363 in Participants With Refractory Autoimmune Diseases",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:15:11.740957Z","2026-06-16T05:54:07.853790Z",{"nct_id":112,"title":113,"phases":114,"status":108,"updated_at":115,"content_modified":116},"NCT05979441","A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy",[77],"2026-08-26T02:15:42.447052Z","2026-06-16T05:54:08.093063Z",{"nct_id":118,"title":119,"phases":120,"status":108,"updated_at":121,"content_modified":122},"NCT06375993","A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease",[20],"2026-08-26T02:16:24.970704Z","2026-06-16T05:54:07.753503Z",{"nct_id":124,"title":125,"phases":126,"status":127,"updated_at":128,"content_modified":129},"NCT06665256","Phase 2 Study of Rapcabtagene Autoleucel in Myositis",[57],"ACTIVE_NOT_RECRUITING","2026-08-03T02:14:31.240767Z","2026-05-05T02:43:28.530829Z",[],[132,136,140,144,148,152,156,160,163,166,170,173,176,179,182,185,188,192,195,198,201,204,207,210],{"state":133,"count":134,"slug":135},"North Carolina",13,"north-carolina",{"state":137,"count":138,"slug":139},"California",12,"california",{"state":141,"count":142,"slug":143},"Florida",11,"florida",{"state":145,"count":146,"slug":147},"New York",10,"new-york",{"state":149,"count":150,"slug":151},"Illinois",9,"illinois",{"state":153,"count":154,"slug":155},"Texas",7,"texas",{"state":157,"count":158,"slug":159},"Arizona",5,"arizona",{"state":161,"count":158,"slug":162},"Iowa","iowa",{"state":164,"count":158,"slug":165},"Pennsylvania","pennsylvania",{"state":167,"count":168,"slug":169},"Georgia",4,"georgia",{"state":171,"count":168,"slug":172},"Maryland","maryland",{"state":174,"count":168,"slug":175},"Massachusetts","massachusetts",{"state":177,"count":168,"slug":178},"Michigan","michigan",{"state":180,"count":168,"slug":181},"Minnesota","minnesota",{"state":183,"count":168,"slug":184},"Missouri","missouri",{"state":186,"count":168,"slug":187},"Utah","utah",{"state":189,"count":190,"slug":191},"Alabama",3,"alabama",{"state":193,"count":190,"slug":194},"Colorado","colorado",{"state":196,"count":190,"slug":197},"Kansas","kansas",{"state":199,"count":190,"slug":200},"Nebraska","nebraska",{"state":202,"count":190,"slug":203},"New Jersey","new-jersey",{"state":205,"count":190,"slug":206},"Ohio","ohio",{"state":208,"count":190,"slug":209},"Tennessee","tennessee",{"state":211,"count":190,"slug":212},"Washington","washington"]